Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early outpatient convalescent plasma for high-risk COVID-19
NL-OMON49795Phase 3Completed
- Sponsor
- Erasmus MC
- Start
- Oct 2020
- Countries
- 1
01
Overview
Phase 3, randomised trial of convalescent plasma (Heinrich-Heine University, Duesseldorf) in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Erasmus MC. Primary endpoint: Highest disease status on 5-point ordinal disease severity scale within 28 days. Started Oct 2020; status: completed.
02
Drugs
convalescent plasma (Heinrich-Heine University, Duesseldorf)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON49795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49795.